Wednesday, February 27, 2013

Immunogenicity Session Spotlight: Highly Sensitive Non-Wash Immunoassays for Immunogenicity and PD/PK Studies

Severe adverse events to biologics are one of the very greatest fears facing the industry – even in a pre-marketing state, if they surface during clinical trials the public fear and reputational damage can be great enough to destroy the sponsor company (as was the case with the infamous “Elephant Man” trials in England). Since one of the quickest ways to predict and pre-empt adverse events is to detect anti-drug antibodies as early as possible and in the lowest amounts possible, this session will help experts in this field specifically target one of the greatest threats they face.  We'll be looking at this during the Highly Sensitive Non-Wash Immunoassays for Immunogenicity and PD/PK Studies session at Immunogenicity for Biotherapeutics this March!

Immunogenicity for Biotherapeutics will take place March 18-20, 2013 in Baltimore, Maryland. For more information on this session and the rest of the agenda, download the brochure. If you'd like to join us, as a reader of this blog when you register to join us and mention code XP1838BLOG, you'll save 15% off the standard rate!

Featured Session: Highly Sensitive Non-Wash Immunoassays for Immunogenicity and PD/PK Studies

Featured Speaker: Roger Bosse, Global Product Leader, Alpha Technology, PERKIN ELMER

About the session: Biotherapeutics often elicit immune responses and clinical consequences of anti-drug antibodies (ADA) can result in adverse events. The presence of ADA is a safety concern and must be evaluated and correlated with pharmacological or toxicological observations. The development of rapid, sensitive assays for ADA detection is essential. AlphaLISAÃ’ assays used to detect ADA in serum samples can detect ADA in the low ng/mL range, maintain excellent performance in serum and exhibit high drug tolerance.


Share this article with your social network, just click below to share now!


No comments :

Post a Comment